Narcolepsy Wake-Sleep Boundary

Narcolepsy wake-sleep boundary is the source’s explanation of narcolepsy as a disorder where the boundary between sleep and waking is blurred. In Wake-up haul: an Ozempic moment for the brain, the condition can involve sudden sleep and, in severe forms, cataplexy.

The concept matters because it gives Orexin Agonists their first grounded medical target. The episode says people with narcolepsy lack enough orexin molecules in the brain, and it uses Emmanuel Mignot’s dog research to explain how orexin became central to the disease story.

Key Claims

• Narcolepsy is presented as rare, affecting roughly one in 1,000 to one in 2,000 people worldwide in the source’s account.
• Orexin biology turns narcolepsy from a symptom description into a drug-target story.
• Ovoperextone and company work by Takeda Pharmaceutical / 武田制药, Alkermes, and Eli Lilly make the condition the first commercial test for the broader orexin category.
• Broader neuropsychiatric uses remain less grounded than narcolepsy in this source.

Connections

• Orexin Agonists, Ovoperextone, and Emmanuel Mignot - drug, product, and discovery context.
• Takeda Pharmaceutical / 武田制药, Alkermes, Eli Lilly, and Sentessa Pharmaceuticals - company context.
• Sleep Duration U-Shape and Sleep Anxiety Loop - adjacent sleep-health pages with different evidence bases.